Other standardised services and primary tests:
- Mouse/rat model generation, their full characterisation and their delivery in the form of animals or frozen archived lines
- Establishment of a precise genetic (using genome editing) or induced models of a human disease with characterisation of disease development
- Preclinical compound/treatment testing, including GLP mode
- PDX development and characterisation
- Comprehensive report with statistical evaluation
The details on individual screens of the Phenotyping Module are available HERE.
In addition to standardised primary tests, CCP offers secondary (specialised or deep-drilling) tests that can be customised to meet user needs.
CCP is also developing preclinical testing procedures to support translation of the research into application, including PDX (Patient-Derived Tumour Xenograft) technology studying the development of human tumours.
Furthermore, a state-of-the-art laboratory for the study of infections at the BSL-3 biosafety level for animal work was opened in spring 2023. The lab is equipped for advanced research and testing of human pathogens, such as SARS-CoV-2 and hepatitis. The facility is designed for long-term experiments and preclinical testing of antivirals, as well as efficacy studies and testing of other drugs against human pathogens. More information HERE